title: Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.
authors.forename: A
authors.initials: A
authors.lastname: Jenke
authors.forename: J
authors.initials: J
authors.lastname: Freiberg-Richter
authors.forename: C
authors.initials: C
authors.lastname: Johne
authors.forename: H
authors.initials: H
authors.lastname: Knoth
authors.forename: E
authors.initials: E
authors.lastname: Schleyer
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002066:Busulfan / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D010599:Pharmacokinetics; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine